Speakers to be invited(Ranking regardless)
|
Brian K KASPAR, Ph. D, Chief Scientific Officer, AVEXIS Inc., USA The main focus of the Kaspar laboratory is centered on the mechanism(s) of neurodegeneration in Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). The laboratory works on muscle enhancing strategies in order to combat musculoskeletal disorders as well. They are currently in a Phase I/II human clinical trial for Becker Muscular Dystrophy and Inclusion Body Myositis using their expertise in Adeno Associated Virus. Furthermore, they have advanced human trials for gene delivery in Spinal Muscular Atrophy. |
|
Brian R. ROBINSON, MD, Vice President, Medical Affairs, Bluebirdbio, USA |
|
Chen LI, MD, Peking Union Medical College |
|
Cheng-hua LEE, Ph.D., Deputy Director General, National HealthInsurance Administration Ministry of Health and Welfare, Taiwan, China |
|
Christina WATERS, Ph. D, MBA, President/CEO/Founder, RARE Science Inc., USA |
|
Francis X. McCORMACK, MD, Professor, Department of Internal Medicine, University of Cincinnati School of Medicine, USA |
|
Guangping GAO, Ph.D, Professor, Microbiology & Physiological Systems, Penelope Booth Rockwell Professor in Biomedical Research, Director, Horae GeneTherapy Center and Vector Core, University of Massachusetts Medical School, USA |
|
Harvey F. LODISH, Ph. D, Professor of Biology and Professor of Bioengineering, Massachusetts Institute of Technology, USA |
|
Kevin Rufang HUANG, President of Chinese Organization for Rare Disorders, China |
|
Manuel POSADA, Director, Institute of Rare Diseases Research, ISCIII & President of ICORD, Spain Manuel Posada, MD, PhD in Medicine. He is a specialist in Internal Medicine and also specialist in Public Health and Preventive Medicine, Autonomous University, Madrid, Spain. Director of the Institute of Rare Diseases Research (IIER), Institute of Health Carlos III, and also Director of the National Biobank on Rare Diseases (ISCIII) and the National Rare Diseases Registry. He is the current President of ICORD.
|
|
Mark J. PYKETT, VMD, MD, Presidet/CEO, Agilis Biotherapeutics,USA |
|
Meryem NIMOUR, MD, Vice President, Medical Affairs for Rare Disease in Emerging Markets, Pfizer, USA |
|
Mengchun GONG, MD, Executive Director, National Rare Disease Registry System, China Medical Informatics Consultant, Fudan University, Children’s Hospital Graduated from Peking Union Medical College with a Medical Doctor degree in 2011, Dr. Gong Mengchun entered PUMC Hospital and accomplished the internal residency training in 2014. He also worked in University of California, San Francisco as a visiting scholar in 2014. He joined InterSystems as the Physician Executive in 2015 and brought the advanced medical informatics technologies worldwide to Chinese hospitals and institutes. From 2016, He took the position of the Executive Director of the National Rare Diseases Registry System of China and started to lead the team, composed of over 20 medical institutes in China, to build this nation-wide patient registry system for more than 50 kinds of rare diseases, aiming to recruit over 50, 000 cases in 5 years. Dr. Gong also hold the position of Medical Informatics Consultant for the Translational Medicine Center of Fudan Univeristy, Children’s Hospital, which is ranked as the No.1 Children’s Hospital in China and is one of the leading institutes to provide medical genetics consultancy service to inherited diseases. The major research area of Dr. Gong is medical informatics, covering the directions of ontologies/terminologies, clinical natural language processing, phenotyping based on EMR, integration of phenome and biological omics data and the further data mining . |
|
Raman RAJAKANTH, Executive Director, Rainbow Across Border, Singapore |
|
Renchi YANG, MD, Director, Institute of Hematology, Chinese Academy of Medical Sciences, China |
|
Shuyang ZHANG, Vice President, Peking Union Medical College Hospital, China |
|
Terence R.FLOTTE, MD, Provost, Dean and Professor, Horae Gene Therapy Center, University of Massachusetts Medical School, USA |
|
Wendy CHUNG, MD, PhD, Kennedy Family Professor of Pediatrics and Medicine, Columbia University, USA |
|
Xiarong LI, Ph.D, CEO/Founder, GeneDock, China |
|
Xiaochun LIANG, Professor, Director of Chinese Traditional Medicine, Peking Union Medical College Hospital, China |
|
Xuefan GU, MD, Ph.D,Vice President, Director, Xin Hua Hospital Affiliated to Shanghai Jiaotong University, China |
|
Yaping YANG, Ph. D, FACMG, Baylor Genetics, Baylor College of Medicine, USA |
|
Wei ZHANG, Ph.D, Director of AmCare Genomics Laboratory, China Dr. Zhang is a fellow of American College of Medical Genetics and has extensive research experience and robust scientific training in both clinical and research laboratories. He pioneered the gene-to-structure approach in studying genetic variation in human diseases. He has written more than 70 peer-reviewed scientific publications. His current research focuses on elucidating the genotype-phenotype correlation by studying genetic variations in human genome through gene-to-structure approach. His clinical research interest is in the translational medicine focusing on bringing the state-of-the-art massively parallel sequencing technologies to clinical laboratory, addressing the key questions regarding clinical sensitivity and specificity. |
|
Zhenhua DONG, Professor, Chinese Traditional Medicine, Peking Union Medical College Hospital, China Dr. Zhenhua Dong focuses on the following research areas - diagnosis and treatment method, internal diseases and intractable diseases, especially in rheumatism, chronic liver diseases, and gynecopathy. At the moment, among other things, he is the director of China Association of Chinese Medicine, the deputy director of the rheumatism branch of China Association of Chinese Medicine, the vice president of the professional committee of the rheumatism branch of World Federation of Chinese Medicine, and a senior editor of the journal World Journal of Integrated Traditional and Western Medicine and Rheumatism and Arthritis.
|
Ana RATH, Ph. D, Director, Orphanet, France
Durhane WANG-RIEGER, President, Canadian Organization for Rare Disorders, Canada
Hugh DAWKINS, Director of the Office of Population Health Genomics (OPHG), Public Health Division, Australia
Jianmin LIU , Professor, Director of Endocrinology Department, RuiJin Hospital Shanghai Jiao Tong University of Medicine, China
Jim GREEN, President, International Niemann-Pick Disease Alliance, UK
Junshuai LIU , Labor and Social Security Office of Qingdao, China
Kaixian CHEN ,Academician of Chinese Academy of Science,professor of medicine,China
Ming QI , Professor of foundation medicine, Zhe Jiang University School of Medicine, China
Peter BAUER, Professor, Institute of Medical Genetics and applied Genomics, University Hospital Tübingen, Tübingen, Germany
Xiarong LI , Ph.D, CEO/founder, Genedock, China
Stephen C.GROFT, Pharm.D, Senior Advisor to the Director, National Center for Advancing Translational Sciences, NIH, USA
Tao DUAN , Professor, Chief Physician, Obstetrical Department, Shanghai First Maternity and Infant Hospital, China
Wenhao ZHOU , Professor, Vice-President of Fudan University Pediatric Hospital, China
Weihong GU , Ph.D, China-Japan Friendship Hospital, China
Xue ZHANG , professor,vice president, Graduate School of Peking Union Medical College Hospital, China
Yicheng ZHU , Professor, Vice Director of Neurology, Peking Union Medical College Hospital, China
Zhicheng JING , Professor, Chief of Scientific Research Department, Fuwai Hospital, China